Anthera has switched gears as they recently disclosed that development program testing blisibimod in lupus is on hold as the company searches for a partner that will fund further development. This is a disappointment as ANTH had previously planned to start Phase III development for lupus this year. ANTH now says that that they are[…]
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.